Human Bone morphogenetic protein receptor Ⅱ,BMPR-Ⅱ ELISA Kit

Instructions
Code CSB-E04516h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name bone morphogenetic protein receptor, type II (serine/threonine kinase)
Alternative Names BMP type II receptor ELISA Kit; BMP type-2 receptor ELISA Kit; BMPR 2 ELISA Kit; BMPR 3 ELISA Kit; BMPR II ELISA Kit; BMPR-2 ELISA Kit; BMPR-II ELISA Kit; Bmpr2 ELISA Kit; BMPR2_HUMAN ELISA Kit; BMPR3 ELISA Kit; BMPRII ELISA Kit; BMR 2 ELISA Kit; BMR2 ELISA Kit; Bone morphogenetic protein receptor type 2 ELISA Kit; Bone morphogenetic protein receptor type II ELISA Kit; Bone morphogenetic protein receptor type-2 ELISA Kit; Bone morphogenic protein receptor type II serine threonine kinase ELISA Kit; BRK 3 ELISA Kit; BRK3 ELISA Kit; PPH 1 ELISA Kit; PPH1 ELISA Kit; Serine threonine kinase type II activin receptor like kinase ELISA Kit; T ALK ELISA Kit; TALK ELISA Kit; Type II activin receptor like kinase ELISA Kit
Abbreviation BMPR2
Uniprot No. Q13873
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 6.25 pg/mL-400 pg/mL
Sensitivity 1.56 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cardiovascular
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human BMPR-II in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %92
Range %86-96
1:2Average %99
Range %95-102
1:4Average %90
Range %85-94
1:8Average %99
Range %92-103
Recovery
The recovery of human BMPR-II spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9387-96
EDTA plasma (n=4)9388-97
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
4002.492 2.437 2.465 2.301
2002.054 2.076 2.065 1.901
1001.671 1.634 1.653 1.489
501.074 1.043 1.059 0.895
250.671 0.653 0.662 0.498
12.50.483 0.477 0.480 0.316
6.250.271 0.264 0.268 0.104
00.162 0.166 0.164
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6.
Gene References into Functions
  1. Heterozygous germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable pulmonary arterial hypertension, and in approximately 20% of cases of idiopathic pulmonary arterial hypertension. [review] PMID: 29032562
  2. Tumour necrosis factor-alpha selectively reduces BMPR-II transcription and mediates post-translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells. PMID: 28084316
  3. miR-23a facilitated cell proliferation and migration by targeting BMPR2/Smad1 signaling in hypoxia-induced human pulmonary artery smooth muscle cells. PMID: 29864909
  4. we employed an shRNA-encoding lentivirus system to inhibit SPG6 expression in AML cells including NB4 and MV4-11cells. Knockdown expression of SPG6 resulted in decreased cell growth and elevated apoptosis of these leukemia cells. Notably, SPG6 deficiency resulted in higher BMPR2 expression indicating that BMPR2 signaling contributes to AML pathogenesis. PMID: 29715457
  5. Sequencing of BMPR2, CAV1, and KCNK3 coding regions did not identify any pathogenic variants in these genes in infants with pulmonary hypoplasia and pulmonary hypertension. PMID: 28162765
  6. The present study showed that deletion-duplication mutations in the BMPR2 or ACVRL1 genes may not be associated with non-regression of Pulmonary arterial hypertension. PMID: 28290170
  7. BMPR2 mutation carriers are more prone to hemoptysis and that hemoptysis is closely correlated to bronchial arterial remodelling and angiogenesis; in turn, pronounced changes in the systemic vasculature correlate with increased pulmonary venous remodelling, creating a distinctive profile in pulmonary arterial hypertension patients harbouring a BMPR2 mutation. PMID: 27811071
  8. Studying the methylation pattern of the BMPR2 promoter region in pulmonary arterial hypertension patients and controls revealed a a CpG island, suitable for methylation, in the BMPR2 promoter region, in addition to NIT-2, sex-determining region Y, and heat shock factor transcription factor binding sites.No evidence of methylation was detected in this region in patients and controls. PMID: 26654628
  9. Mutations in the bone morphogenetic protein receptor type-2 gene (BMPR2) have been identified in patients with pulmonary arterial hypertension. PMID: 27248591
  10. Affected mutation carriers with heritable pulmonary hypertension have hypermethylation of the BMPR2 promotor compared with their unaffected relatives. PMID: 28170297
  11. increased BMPR2 signal transduction is linked to fragile X syndrome (FXS) and that the BMPR2-LIMK1 pathway is a putative therapeutic target in patients with FXS and possibly other forms of autism PMID: 27273096
  12. A burden of rare variants in BMPR2 significantly contributed to the risk of pulmonary arterial hypertension. In the remaining one family, the patient carried a pathogenic variant in a member of potassium channels, KCNK3, which was the first replicative finding of channelopathy in an Asian population. PMID: 28388887
  13. The SMYD2 may promote BMP signaling by directly methylating BMPR2, which, in turn, stimulates BMPR2 kinase activity and activation of the BMP pathway. PMID: 28588028
  14. This review focuses on recent advances in rescuing BMPRII expression, function or signaling to prevent and reverse pulmonary vascular remodeling in pulmonary arterial hypertension and its feasibility for clinical translation. Furthermore, it summarizes the role of described miRNAs that directly target the BMPR2 gene in blood vessels. [review] PMID: 28447104
  15. Endothelial BMPR2 signaling in pulmonary arterial hypertension is impaired by deletion of Vegfr3. PMID: 28356442
  16. Disrupting BMPR2 impairs TGFbeta1- and BMP4-mediated elastic fiber assembly and is of pathophysiologic significance in pulmonary arterial hypertension. PMID: 28619995
  17. Cav-1 depletion, oxidative stress-mediated reduction in BMPRII expression, and enhanced TGF-beta-driven SMAD-2/3 signaling promote pulmonary vascular remodeling in inflamed lungs. PMID: 28188225
  18. This analysis identified features of unaffected mutation carriers iPSC-induced pluripotent stem cell-derived endothelial cells related to modifiers of BMPR2 signaling or to differentially expressed genes. PMID: 28017794
  19. Decreased expression of bone morphogenetic protein receptor type 2 (BMPR2) is associated with all forms of PAH, and a mutation in this receptor is seen in 70% of patients with the heritable form of PAH (HPAH), and in 20% of sporadic cases of idiopathic PAH. PMID: 27779452
  20. HPAH-associated BMPRII mutation increases pulmonary microvascular endothelial cells adhesiveness for monocytes in response to inflammatory mediators. PMID: 27816994
  21. BMPR2 downregulation may have a role in neuroblastoma PMID: 27998774
  22. Bone morphogenetic protein 2 expression increases and may contribute to partitioning of energy storage into visceral and subcutaneous AT depots PMID: 27515773
  23. Depletion of BMPR2 mediated by a collection of miRs induced by IL6 and subsequent STAT3 phosphorylation is a novel mechanism participating to fibroproliferative and vascular injuries in idiopathic pulmonary fibrosis. PMID: 27317687
  24. Pathogenic BMPR2 mutations were identified in 8 of 72 (11.1%) patients with IPAH and 6 of 9 (66.7%) patients with HPAH. PMID: 27884767
  25. In a cohort with idiopathic or hereditary pulmonary arterial hypertension, a possibly associated mutation was found in 11.10% of the idiopathic cases (n = 16) and in 68.18% of the hereditary cases. There were 19 mutations found in BMPR2. PMID: 27453251
  26. Case Report: sarcoid-like reaction due to pulmonary hypertension in the context of the BMPR2 mutation. PMID: 27537724
  27. Patients with pulmonary arterial hypertension and bone morphogenetic protein receptor type II mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations. PMID: 26795434
  28. Study of four patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection found predisposing mutations in the BMPR2, ACVRL1 and ENG genes. PMID: 26897508
  29. BMPR2 mutations were identified in congenital heart disease-pulmonary vascular disease patients, with missense mutation of BMPR2 as the dominant mutation type. PMID: 27002414
  30. his study demonstrated that both rs6435156C > T and rs1048829G > T variants in BMPR2 contributed to increased susceptibility to hronic obstructive pulmonary disease PMID: 27077124
  31. Increased HMGA1 in pulmonary arterial endothelial cells resulting from dysfunctional BMPR2 signaling can transition endothelium to smooth muscle-like cells associated with pulmonary arterial hypertension. PMID: 27045138
  32. Pulmonary arterial hypertension patients carrying a BMPR2 mutation have decreased right ventricular function compared to patients without the mutation. PMID: 26984938
  33. the data in the present study support the notion that the expression levels and plasma membrane levels of BMPRII are determined by two molecular processes-translational regulation of protein synthesis (which provides the major contribution) and endocytosis/degradation (mild modulatory effect). PMID: 26739752
  34. In a group of pulmonary arterial hypertension patients, 25.4% harboured heterozygous mutation in the BMPR2 gene. PMID: 26541523
  35. establish the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2 osteogenesis PMID: 26772960
  36. Raf family members and ERK1/2 were constitutively activated after BMPR2 knockdown PMID: 26589479
  37. miR-153 is a mechano-sensitive miRNA that regulates osteoblast differentiation by directly targeting BMPR2, and that therapeutic inhibition of miR-153 may be an efficient anabolic strategy for skeletal disorders caused by pathological mechanical loading. PMID: 26151470
  38. study shows for the first time that in the regulatory region of the BMPR2 gene the promoter may be important for pulmonary arterial hypertension penetrance PMID: 26167679
  39. Correlations between C23, BMPRII expression and prognosis of gastric cancer patients. PMID: 25698539
  40. local gene transfection can up-regulate the expression of osteogenic mediators (BMP-2 and TGF-beta1), which may promote cell differentiation and proliferation and stimulate extracellular matrix synthesis and new bone formation in distraction gap. PMID: 25723654
  41. BMP2 decreased serum-induced proliferation and increased the pro-apoptotic Bax/Bcl-2 ratio. These effects were attenuated by endothelin-1 pre-treatment PMID: 25447587
  42. our results showed that GDF-5 and BMPRII expressed both in normal and degenerated intervertebral disc tissues, and GDF-5 might have an inhibition effect on degenerated lumbar intervertebral discs PMID: 25755766
  43. The BMPR2 protein containing Thr268fs, Ser863Asn, or Gln433X exhibited abnormal subcellular localization. PMID: 25187962
  44. Mutations in BMPR2 gene is associated with pulmonary arterial hypertension. PMID: 24936649
  45. Mutations in BMPR2 underlie most heritable cases and a small proportion of sporadic cases of idiopathic pulmonary arterial hypertension. Read More: http://www.atsjournals.org/doi/full/10.1164/rccm.201408-1528OC#.Viqgi9KFPyA PMID: 26030479
  46. BMP9 is identified as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in endothelial cells from subjects with pulmonary arterial hypertension who bear mutations in the gene encoding BMPR2. PMID: 26076038
  47. Silencing BMPR2 promoted G2/M cell cycle arrest and apoptosis through caspase-3-dependent pathway via repression of XIAP and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway. PMID: 25501832
  48. Mutations in BMPR2 encoding bone morphogenetic protein receptor type 2 (BMPRII) is the main genetic risk factor for heritable pulmonary arterial hypertension PMID: 25429696
  49. disrupted intracellular trafficking of BMPR2 is involved in the pathogenic mechanism underlying both cysteine and non-cysteine substitutions occurring in the extracellular ligand binding domain and kinase domain of BMPR2. PMID: 25688877
  50. Combining mutation detection in family members with parental identification, study described three cases of de novo mutation in the BMPR2 gene by different modes in a pulmonary arterial hypertension family. These de novo mutations may account for the wide variety of mutations in BMPR2. PMID: 25612240

Show More

Hide All

Involvement in disease Pulmonary hypertension, primary, 1 (PPH1); Pulmonary venoocclusive disease 1, autosomal dominant (PVOD1)
Subcellular Location Cell membrane, Single-pass type I membrane protein
Protein Families Protein kinase superfamily, TKL Ser/Thr protein kinase family, TGFB receptor subfamily
Tissue Specificity Highly expressed in heart and liver.
Database Links

HGNC: 1078

OMIM: 178600

KEGG: hsa:659

STRING: 9606.ENSP00000363708

UniGene: Hs.471119

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1